Form 4: VolitionRx Singapore CEO's RSU Vesting Update

Jasmine Kway, CEO of VolitionRx Singapore, reported the vesting of 42,000 restricted stock units and the cancellation of 98,000 units.

Summary

• Jasmine Kway, CEO of VolitionRx Singapore, reported changes in her beneficial ownership of VolitionRx Ltd. common stock.
• She was awarded 140,000 restricted stock units (RSUs) on March 17, 2025, under the Issuer's 2024 Stock Incentive Plan.
• 42,000 of these RSUs vested due to the achievement of certain corporate performance goals.
• These 42,000 vested RSUs are subject to a 3-year time-based vesting schedule, with 14,000 units vesting annually on March 17, 2026, 2027, and 2028.
• The remaining 98,000 RSUs did not vest and were cancelled on June 30, 2025, and January 22, 2026.
• Following the reported transaction, Ms. Kway beneficially owns 245,614 shares directly and 10,400 shares indirectly through her spouse.

Sentiment

Score: 6

Explanation: The vesting of 42,000 RSUs is a positive sign of performance goal achievement, aligning executive incentives. However, the cancellation of 98,000 RSUs suggests that a larger portion of performance targets were not met, leading to a mixed sentiment.

Positives

• 42,000 restricted stock units (RSUs) vested for Jasmine Kway, indicating the achievement of certain corporate performance goals.
• The vesting of these RSUs will result in the future receipt of common stock, aligning management incentives with shareholder value.

Negatives

• 98,000 restricted stock units (RSUs) did not vest and were cancelled, suggesting that some corporate performance goals were not met.

Future Outlook

The vesting schedule for the 42,000 RSUs extends through March 2028, indicating a long-term incentive structure for the CEO of VolitionRx Singapore.

Corporate Governance

Stakeholder Impact

• Shareholders: The vesting of RSUs aligns executive incentives with shareholder interests, as it's tied to corporate performance. The cancellation of a larger portion of RSUs indicates that some performance targets were not met, which could be viewed neutrally or slightly negatively depending on the specific targets.
• Employees: The compensation structure for a key executive provides insight into the company's overall approach to performance-based incentives.

Next Steps

• The remaining 28,000 units of the vested RSUs will vest in two equal installments of 14,000 units on March 17, 2027, and March 17, 2028.
• Upon vesting and settlement, Jasmine Kway will receive shares of common stock equal to the number of RSUs that have vested.

Key Dates

Recommendation

This Form 4 filing primarily details routine executive compensation adjustments based on pre-defined performance and time-based vesting schedules. While 42,000 RSUs vested due to met performance goals, a larger portion of 98,000 RSUs were cancelled due to unmet goals, presenting a mixed picture of performance. This type of insider transaction is generally not a strong indicator for a "buy" or "sell" recommendation on its own, as it reflects past performance against specific targets rather than new strategic direction or significant financial news. Therefore, a "hold" recommendation is appropriate, pending further comprehensive financial and strategic updates from VolitionRx.

Keywords

VolitionRx, VNRX, Form 4, SEC filing, insider trading, restricted stock units, RSU vesting, executive compensation, Jasmine Kway, stock incentive plan